These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23185256)

  • 1. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya.
    Njomo DW; Amuyunzu-Nyamongo M; Magambo JK; Njenga SM
    PLoS One; 2012; 7(11):e48395. PubMed ID: 23185256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya.
    Njomo DW; Kimani BW; Kibe LW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0009012. PubMed ID: 33370300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach.
    Njomo DW; Kibe LW; Kimani BW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008499. PubMed ID: 32936792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya.
    Kusi C; Steinmann P; Merten S
    Infect Dis Poverty; 2020 Mar; 9(1):22. PubMed ID: 32114985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya.
    Njomo DW; Mukoko DA; Nyamongo NK; Karanja J
    PLoS One; 2014; 9(1):e83413. PubMed ID: 24454703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge and practice related to compliance with mass drug administration during the Egyptian national filariasis elimination program.
    Abd Elaziz KM; El-Setouhy M; Bradley MH; Ramzy RM; Weil GJ
    Am J Trop Med Hyg; 2013 Aug; 89(2):260-4. PubMed ID: 23751402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Awareness and coverage of mass drug administration for elimination of lymphatic filariasis: a community based cross sectional study in Nepal.
    Adhikari RK; Sherchand JB; Mishra SR; Ranabhat K; Wagle RR
    J Community Health; 2015 Feb; 40(1):34-40. PubMed ID: 24996654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained reduction in prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug administration in an area under mosquito nets for malaria control.
    Njenga SM; Mwandawiro CS; Wamae CN; Mukoko DA; Omar AA; Shimada M; Bockarie MJ; Molyneux DH
    Parasit Vectors; 2011 May; 4():90. PubMed ID: 21612649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study.
    Lahariya C; Mishra A
    J Vector Borne Dis; 2008 Dec; 45(4):313-20. PubMed ID: 19248659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of community compliance with spaced, single-dose, mass administrations of diethylcarbamazine or ivermectin, for the elimination of lymphatic filariasis from rural areas of southern India.
    Vanamail P; Ramaiah KD; Subramanian S; Pani SP; Yuvaraj J; Das PK
    Ann Trop Med Parasitol; 2005 Apr; 99(3):237-42. PubMed ID: 15829133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
    Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
    Lupenza ET; Gasarasi DB; Minzi OM
    PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coverage and compliance of mass drug administration (MDA) programme for elimination of lymphatic filariasis in an endemic district of eastern Uttar Pradesh, India.
    Bashar A; Nandekar SV; Shrivastava P; Singh RN; Srikrishnan P
    J Vector Borne Dis; 2023; 60(3):307-316. PubMed ID: 37843242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatic filariasis elimination programme in Andaman and Nicobar Islands, India: drug coverage and compliance post eight rounds of MDA.
    Sunish IP; Shriram AN; Sivan A; Kartick C; Saha BP; Vijayachari P
    Trop Doct; 2013 Jan; 43(1):30-2. PubMed ID: 23550201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia.
    Krentel A; Wellings K
    Parasit Vectors; 2018 Mar; 11(1):179. PubMed ID: 29530082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India.
    Roy RN; Sarkar AP; Misra R; Chakroborty A; Mondal TK; Bag K
    J Health Popul Nutr; 2013 Jun; 31(2):171-7. PubMed ID: 23930334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
    Krentel A; Fischer P; Manoempil P; Supali T; Servais G; Rückert P
    Trop Med Int Health; 2006 Nov; 11(11):1731-40. PubMed ID: 17054754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
    Babu BV; Kar SK
    Trop Med Int Health; 2004 Jun; 9(6):702-9. PubMed ID: 15189460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.